NUP188 Antibody is a polyclonal antibody targeting the nucleoporin NUP188, a 196 kDa scaffold protein of the nuclear pore complex (NPC). This antibody is widely used to study NUP188's dual roles in nuclear transport and mitotic regulation . Commercial variants are available from suppliers such as Affinity Biosciences (Catalog: DF14116), Thermo Fisher Scientific (PA5-66645), and Abcam (ab204490), with applications in immunohistochemistry (IHC), immunofluorescence (IF), and Western blotting (WB) .
NUP188 localizes to centrosomes during mitosis and interacts with NuMA (Nuclear Mitotic Apparatus protein), which is critical for spindle pole organization . Depletion of NUP188 disrupts K-fiber formation, leading to chromosome misalignment and mitotic arrest . Key findings include:
Centrosomal Localization: The C-terminal region of NUP188 mediates its recruitment to centrosomes, peaking during metaphase .
NuMA Interaction: NUP188 depletion reduces NuMA localization at spindle poles, impairing microtubule focusing .
NUP188 is part of the Nup93 subcomplex, which regulates nuclear membrane integrity by controlling the passage of membrane proteins between the outer (ONM) and inner nuclear membranes (INM) . Depleting NUP188 increases NPC density threefold but does not impair active nuclear transport .
The centrosomal pool of NUP188 undergoes proteasomal degradation, while the NPC pool remains stable. Pulse-chase experiments show newly synthesized NUP188 populates centrosomes independently of NPC exchange .
NUP188 resides on chromosome 9q34, a region frequently deleted in B-cell acute lymphoblastic leukemia (B-ALL) . Overexpression of nucleoporins like NUP88 is linked to tumorigenesis, while NUP188 depletion causes aneuploidy and mitotic defects .
NUP188 binds Cep152, a centriole duplication factor, and regulates Sas6 loading—a critical step in centriole assembly .
Chromosome Alignment Studies: Used to validate NUP188’s role in K-fiber stabilization via siRNA depletion and rescue experiments .
Super-Resolution Microscopy: Localizes NUP188 within 100 nm of the centriole core, adjacent to Cep152 .
Proximity-Labeling: Identified interactions with Cep192 and PCM1, linking NUP188 to centrosomal matrix organization .
KEGG: sce:YML103C
STRING: 4932.YML103C
NUP188 (Nucleoporin 188) is a component of the nuclear pore complex (NPC) that plays a critical role in trafficking across the nuclear envelope. In humans, the canonical protein consists of 1749 amino acid residues with a molecular mass of 196 kDa . As a member of the Nup188 protein family, it is required for proper protein transport into the nucleus and contributes to maintaining nuclear envelope integrity . The protein exists in two isoforms resulting from alternative splicing and is primarily localized to the nucleus . NUP188 interacts specifically with Nup93 to form a distinct complex that differs from the Nup205-Nup93 complex, indicating functionally specialized roles within the nuclear pore architecture .
NUP188 antibodies are employed in multiple experimental applications with varying protocols depending on the research question. The primary applications include:
Western Blotting (WB): For detection of denatured NUP188 protein in cell and tissue lysates
Immunohistochemistry (IHC-p/IHC-f): For visualization of NUP188 in paraffin-embedded or frozen tissue sections
Immunocytochemistry/Immunofluorescence (ICC/IF): For cellular localization studies
Immunoprecipitation (IP): For isolation of NUP188 protein complexes
Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of NUP188
The optimal application depends on experimental goals, with different antibodies showing varying sensitivities and specificities across these techniques.
For Western blotting, samples should be thoroughly denatured, with optimal results typically achieved using RIPA or NP-40 based lysis buffers. For immunohistochemistry, paraformaldehyde fixation at 4% has been validated for human endometrium tissue sections with NUP188 antibodies used at dilutions of 1:20 . For immunofluorescence, paraformaldehyde-fixed cells (such as SiHa cells) have been successfully labeled with NUP188 antibodies at concentrations of 4 μg/ml . Epitope retrieval techniques differ between antibodies, with some requiring high-pH retrieval solutions while others work optimally with low-pH conditions. Each application should be optimized with proper positive and negative controls.
This size regulation appears to be specific to the Nup188-Nup93 complex, as depletion of the Nup205-Nup93 complex does not result in similar changes to nuclear volume . The mechanism likely involves regulation of the nuclear diffusion barrier, potentially allowing uncontrolled accumulation of material in the nucleus when the Nup188-Nup93 complex is absent.
To investigate NUP188-dependent protein transport, researchers can employ several complementary approaches:
Immunodepletion studies: Using specific antibodies against NUP188 to deplete the protein from model systems such as Xenopus egg extracts, followed by functional transport assays .
CRISPR-Cas9 gene editing: Creating knockout or knockdown cell lines to evaluate the effects of NUP188 absence on specific transport pathways.
Live-cell imaging: Using fluorescently tagged cargo proteins to track their nuclear import in the presence or absence of functional NUP188.
In vitro transport assays: Reconstituting transport systems with purified components to determine the direct contribution of NUP188.
Co-immunoprecipitation: Identifying transport factors that interact with NUP188 by using antibodies to pull down protein complexes .
When designing such experiments, it's important to distinguish between the effects of Nup188-Nup93 complex depletion versus Nup205-Nup93 complex depletion, as these appear to have distinct functional consequences .
Validating NUP188 antibody specificity is crucial for reliable experimental results. A comprehensive validation approach should include:
Western blot analysis: Confirming the detection of a single band at the expected molecular weight (196 kDa) in relevant samples. Multiple bands may indicate detection of different isoforms or non-specific binding .
Immunoprecipitation followed by mass spectrometry: To verify that the antibody pulls down NUP188 specifically.
Immunostaining pattern assessment: In properly fixed cells/tissues, NUP188 antibodies should show nuclear envelope localization characteristic of nucleoporins .
CRISPR knockout controls: Using NUP188 knockout cells as negative controls to confirm signal specificity.
Peptide competition assays: Pre-incubating the antibody with the immunizing peptide should abolish specific signals.
Cross-reactivity testing: Evaluating antibody reactivity across multiple species if cross-species applications are planned. Many commercially available NUP188 antibodies are reactive with human and mouse samples .
Comparison of multiple antibodies: Using different antibodies raised against distinct epitopes of NUP188 to confirm consistent localization and detection patterns.
The validation approach should be tailored to the specific application for which the antibody will be used.
NUP188 exhibits specific interaction patterns with other nucleoporins that define its functional role in the nuclear pore complex:
Nup93 interaction: NUP188 forms a distinct complex with Nup93, which is separate from the Nup205-Nup93 complex. Quantitative immunoprecipitation experiments show that approximately 45% of Nup93 associates with NUP188 .
Exclusivity with Nup205: Despite both being associated with Nup93, NUP188 and Nup205 do not appear to interact with each other, forming mutually exclusive complexes with Nup93 .
Limited interaction with other nucleoporins: Immunoprecipitation experiments indicate that NUP188 does not substantially interact with Nup53, Nup155, or Nup98, suggesting specific rather than promiscuous interactions within the NPC .
This distinct interaction pattern suggests that NUP188 functions in a specific subcomplex of the NPC with dedicated roles that differ from those of the Nup205-Nup93 complex. The presence of these separate complexes may explain the different functional outcomes observed when each complex is depleted from experimental systems.
When working with NUP188 antibodies, researchers frequently encounter several technical challenges:
High molecular weight detection issues: At 196 kDa, NUP188 requires extended transfer times for Western blotting and special gel concentration considerations (typically 6-8% acrylamide gels) .
Epitope masking: The large size and complex interactions of NUP188 within the nuclear pore complex can result in epitope masking, particularly in fixed samples. This may require optimization of fixation and permeabilization protocols .
Isoform specificity: With multiple isoforms reported, antibodies may detect different subsets of NUP188 proteins depending on the epitope location .
Cross-reactivity concerns: Some antibodies may cross-react with other nucleoporins due to structural similarities within the protein family.
Signal amplification requirements: For techniques like immunohistochemistry, signal amplification methods may be necessary due to relatively low abundance of NUP188 compared to other cellular proteins .
For each application, optimization of antibody dilution, incubation time, temperature, and detection methods is crucial for successful results.
When faced with contradictory results using different NUP188 antibodies, consider the following analytical approach:
Epitope mapping: Compare the epitope regions recognized by each antibody. Antibodies against different domains may yield different results if:
Antibody format differences: Compare polyclonal versus monoclonal antibodies - polyclonals recognize multiple epitopes and may provide stronger signals but potentially higher background .
Validation rigor: Assess the validation data for each antibody. Those with extensive validation (citation records, knockout controls) should be given greater weight .
Application optimization: Each antibody may require specific conditions for optimal performance in different applications (WB, IHC, IF) .
Fixation sensitivity: Test multiple fixation methods as some epitopes are sensitive to specific fixatives or fixation times.
Experimental system variations: Consider whether results differ due to cell type, species, or experimental conditions rather than antibody performance.
When reporting contradictory results, document all variables systematically to identify patterns that may explain discrepancies.
For successful co-immunoprecipitation studies involving NUP188, the following optimized protocol framework is recommended:
Lysis buffer selection: Use gentle lysis buffers (containing 0.5-1% NP-40 or Triton X-100) to preserve protein-protein interactions, particularly the NUP188-Nup93 interaction .
Pre-clearing: Pre-clear lysates with appropriate control IgG and protein A/G beads to reduce non-specific binding.
Antibody selection: Choose antibodies validated for immunoprecipitation applications. For example, rabbit anti-NUP188 antibodies have been successfully used in published studies to precipitate the NUP188-Nup93 complex .
Controls: Include:
IgG control from the same species as the NUP188 antibody
Input sample (5-10% of starting material)
Negative control immunoprecipitation targeting an unrelated protein
Incubation conditions: Perform antibody incubation at 4°C overnight with gentle rotation to maximize specific interactions while minimizing non-specific binding.
Washing stringency: Use low-stringency washes to preserve weaker interactions within the NUP188-containing complexes.
Elution and detection: Elute precipitated complexes under conditions that maintain associated proteins for downstream analysis like Western blotting or mass spectrometry.
This approach has successfully demonstrated that NUP188 forms a complex with Nup93 but not with Nup205, providing evidence for distinct subcomplexes within the nuclear pore complex architecture .
Beyond its established structural role, several emerging research directions for NUP188 include:
Cell cycle regulation: Investigating how NUP188-Nup93 complexes reorganize during mitosis and their potential role in regulating cell cycle progression.
Disease associations: Exploring connections between NUP188 mutations/disruptions and human diseases, particularly those involving nuclear envelope pathologies.
Specialized transport pathways: Determining whether the NUP188-Nup93 complex regulates specific transport pathways distinct from those regulated by the Nup205-Nup93 complex.
Nuclear size regulation: Building on the observation that Nup188-Nup93 depletion leads to enlarged nuclei, investigating the mechanisms by which this complex contributes to nuclear scaling and size homeostasis .
Gene expression regulation: Examining potential roles for NUP188 in gene expression regulation, as nucleoporins have increasingly been implicated in transcriptional control.
Membrane dynamics: Studying how NUP188 might influence nuclear envelope remodeling during processes like nuclear envelope breakdown and reformation.
These research directions represent promising avenues for expanding our understanding of NUP188 biology beyond its structural contributions to nuclear pore complexes.
Different model systems offer distinct advantages for NUP188 research:
Xenopus egg extracts: Ideal for biochemical depletion studies and in vitro nuclear assembly assays. This system has been particularly valuable for demonstrating the role of the Nup188-Nup93 complex in nuclear size regulation .
Human cell lines: Suitable for studying NUP188 in a physiologically relevant context. Cell lines like SiHa have been successfully used for immunofluorescence studies with NUP188 antibodies .
Mouse models: Appropriate for investigating developmental and tissue-specific roles of NUP188, with antibodies showing cross-reactivity to mouse NUP188 .
Reconstituted systems: In vitro reconstitution of minimal NPC components can help elucidate the direct contribution of NUP188 to nuclear pore structure and function.
Yeast models: Though evolutionary distinct, yeast orthologs of NUP188 can provide insights into conserved functions through genetic manipulation approaches not easily achieved in higher eukaryotes.
The choice of model system should align with specific research questions, with consideration given to the availability of reagents like species-specific antibodies and the technical feasibility of experimental approaches.